adalimumab-adaz · Kit

What changed in the last 90 days

Every detected change for adalimumab-adaz, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

Same drug class

Other molecules FDA puts in Tumor Necrosis Factor Blocker, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

• etanercept· 1 maker
• infliximab-axxq· 1 maker
• adalimumab-aqvh· 2 makers
• golimumab· 2 makers
• adalimumab-atto· 3 makers
• adalimumab-bwwd· 3 makers
• certolizumab pegol· 4 makers
• infliximab-dyyb· 4 makers
• infliximab· 8 makers

Common questions

Is Adalimumab-adaz in shortage right now?

No. FDA does not currently list Adalimumab-adaz in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.

Who makes Adalimumab-adaz?

3 companies have marketed Adalimumab-adaz in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.

What does Adalimumab-adaz cost?

The typical pharmacy pays about $1,586.73 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

Shortage reports for this molecule

• Planned discontinuation — Hyrimoz, Injection, Kit (NDC 61314-517-36)Jan 13, 2026
• Planned discontinuation — Hyrimoz, Injection, Kit (NDC 61314-531-64)Jan 13, 2026